NCT02430506View on ClinicalTrials.gov

A Study to Evaluate Safety and Immunogenicity of AERAS-402 Administered in HIV-negative, BCG-vaccinated, QFT (+) and (-) Adults Without Evidence of TB

PHASE1CompletedINTERVENTIONAL
Enrollment

20

Participants

Timeline

Start Date

September 30, 2008

Primary Completion Date

June 30, 2009

Study Completion Date

July 31, 2010

Conditions
Tuberculosis
Interventions
BIOLOGICAL

Placebo

This is the identical buffer solution in which AERAS-402 is formulated.

BIOLOGICAL

AERAS-402

Given to 8 participants that were QFT-G(-) at screening and 8 participants that were GFT-G(+) at screening.

Trial Locations (1)

Unknown

Kenya Medical Research Institute, Kisumu

Sponsors

Lead Sponsor

Aeras
All Listed Sponsors
lead

Aeras

OTHER

NCT02430506 - A Study to Evaluate Safety and Immunogenicity of AERAS-402 Administered in HIV-negative, BCG-vaccinated, QFT (+) and (-) Adults Without Evidence of TB | Biotech Hunter | Biotech Hunter